Contrasting TC Biopharm (NASDAQ:TCBP) & Inhibrx (NASDAQ:INBX)

TC Biopharm (NASDAQ:TCBP) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for TC Biopharm and Inhibrx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0	0	0	0	0.00
Inhibrx	0	2	0	0	2.00

Profitability

This table compares TC Biopharm and Inhibrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Inhibrx	N/A	-113.74%	-80.56%

Institutional & Insider Ownership

16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 22.2% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares TC Biopharm and Inhibrx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76 million	0.06	-$7.35 million	N/A	N/A
Inhibrx	$1.57 million	140.88	-$154.96 million	N/A	N/A

TC Biopharm has higher revenue and earnings than Inhibrx.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Inhibrx

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.